

Communication Address:

Solara Active Pharma Sciences Limited

2nd Floor, Admin Block 27, Vandaloor Kelambakkam Road, Keelakottaiyur Village, Melakottaiyur (Post)

Chennai – 600 127, India Tel: +91 44 43446700 Fax: +91 44 47406190 E-mail: investors@solara.co.in

www.solara.co.in

April 02, 2025

The BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Scrip Code: 541540, 890202

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex

Bandra (E), Mumbai – 400 051 Symbol: SOLARA, SOLARAPP

Dear Sir/Madam.

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Outcome of Rights Issue Committee Meeting dated April 02, 2025

This is to inform you that further to our letter dated March 26, 2025, and pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ('SEBI Listing Regulations'), this is to inform that the Rights Issue Committee of the Board of Directors of the Company at its meeting held today (i.e.) April 02, 2025, inter alia, considered and approved the First Call money Notice, on the partly paid-up Equity Shares issued on Rights basis which is to be sent to the Shareholders

In terms of Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, the Company had fixed Friday, April 04, 2025 to be the Record Date for the purpose of determining the holders of Rights Equity Shares to whom the call notice for the first call will be sent, as already intimated vide our letter dated March 26, 2025.

We request you to take the same on record and the same be treated as compliance under the applicable provisions of the SEBI Listing Regulations, as amended.

The Rights Issue Committee Meeting commenced at 15:00 P.M. and concluded at 15:40 P.M.

Thanking you,
Yours faithfully,
For Solara Active Pharma Sciences Limited

S. Murali Krishna Company Secretary & Compliance Officer Membership No.: A13372

Encl.: As above



Communication Address:

Solara Active Pharma Sciences Limited

2nd Floor, Admin Block 27, Vandaloor Kelambakkam Road, Keelakottaiyur Village, Melakottaiyur (Post)

Chennai – 600 127, India Tel: +91 44 43446700 Fax: +91 44 47406190 E-mail: investors@solara.co.in

www.solara.co.in

Annexure – I

<u>Details under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/ 2023/123 dated July 13, 2023</u>

Sr.	Particulars	Remarks
No.		
1.	Forfeiture of shares	Not Applicable.
2.	Reissue of forfeited shares or securities, or the issue of shares or securities held in reserve for future issue or the creation in any form or manner of new shares or securities or any other rights, privileges or benefits to subscribe to	Not Applicable.
3.	Proposal to issue any class of securities;	Not Applicable
4.	Alterations of capital, including calls;	The first call of ₹ 3.50/- each at a premium of Rs. 127.75/- aggregating to ₹157.48 Crores be made on 1,19,98,755 (One Crore Nineteen Lakhs Ninety-Eight Thousand Seven hundred and fifty-five) partly paid-up equity shares of the Company at a face value of Rs. 10/- each.
5.	Change in the terms regarding redemption/cancellation/retirement in whole or in part of any securities issued by the listed entity	Not Applicable

For Solara Active Pharma Sciences Limited

S. Murali Krishna Company Secretary & Compliance Officer Membership No.: A13372